New Colon Ca Agent Is Available in France
PARIS-Rhône-Poulenc Rorer Inc.'s Campto (irinotecan/CPT-11), the first new therapeutic agent for the treatment of colorectal cancer since the introduction of fluorouracil nearly 40 years ago, is now available in France. France is the first country outside Japan to approve this agent for marketing.
PARIS-Rhône-Poulenc Rorer Inc.'s Campto (irinotecan/CPT-11),the first new therapeutic agent for the treatment of colorectalcancer since the introduction of fluorouracil nearly 40 yearsago, is now available in France. France is the first country outsideJapan to approve this agent for marketing.
Topoisomerase I Inhibitor
Campto is a potent inhibitor of topoisomerase I, an enzyme essentialfor cell division. The drug is indicated for the treatment ofadvanced colorectal cancer that has failed standard chemotherapywith fluorouracil and folinic acid. Side effects include neutropeniaand moderate to severe diarrhea.
In a pivotal phase II trial completed last year, 20% of patients(32 of 156) had a significant response to Campto, 350 mg/m²IV every 3 weeks (one treatment cycle). The median duration ofresponse was 9.1 months (range, 1.6 to 17), and more than onethird of patients were free from disease progression for 6 months,the company said.
Look for a more in-depth report on this new agent in next month'sissue of ONCOLOGY NEWS INTERNATIONAL.
![A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6b7c9a3270c71a70749ba86000cfc78a29d74309-2988x1702.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "A third of patients had a response [to lifileucel], and of the patients who have a response, half of them were alive at the 4-year follow-up.")
![We have the current CAR [T-cell therapies], which target CD19; however, we need others.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6d5ddb2c2098f525a65b378ece6ca55a114f95fc-2974x1660.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "We have the current CAR [T-cell therapies], which target CD19; however, we need others.")
Navigating AE Management for Cellular Therapy Across Hematologic Cancers
A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.
GLP-1 Receptor Agonist Use and Weight Change in Patients With Breast Cancer
Patients with breast cancer experience significant weight loss after using GLP-1 receptor agonists, highlighting potential benefits for obesity management in this population.
